WallStSmart

Axsome Therapeutics Inc (AXSM)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Axsome Therapeutics Inc generates 95350% more annual revenue ($708.24M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -26.6%. AXSM earns a higher WallStSmart Score of 31/100 (F).

AXSM

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 6.7Quality: 3.5
Piotroski: 5/9Altman Z: -2.12

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AXSMUndervalued (+50.8%)

Margin of Safety

+50.8%

Fair Value

$378.56

Current Price

$232.32

$146.24 discount

UndervaluedFair: $378.56Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AXSM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
57.4%10/10

Revenue surging 57.4% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

AXSM4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
219.2x2/10

Trading at 219.2x book value

Return on EquityProfitability
-345.0%2/10

ROE of -345.0% — below average capital efficiency

Free Cash FlowQuality
$-20.82M2/10

Negative free cash flow — burning cash

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : AXSM

The strongest argument for AXSM centers on Revenue Growth. Revenue growth of 57.4% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : AXSM

The primary concerns for AXSM are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 3.97 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

AXSM profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

AXSM is growing revenue faster at 57.4% — sustainability is the question.

AXSM generates stronger free cash flow (-21M), providing more financial flexibility.

Bottom Line

AXSM scores higher overall (31/100 vs 24/100) and 57.4% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Axsome Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United States. The company is headquartered in New York, New York.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?